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Abstract
Background: Epstein-Barr virus (EBV) establishes its latency in EBV-associated malignancies, accompanied by
occasionally reactivated lytic cycle. Promoter CpG methylation of EBV genome plays an essential role in
maintaining viral latency. Two immediate-early (IE) genes, BZLF1 and BRLF1, induce the switch from latent to lytic
infection. Studies of methylation-dependent binding of BZLF1 and BRLF1 to EBV promoters have been well
reported, but little is known about the methylation status of BZLF1 and BRLF1 promoters (Zp and Rp) in tumor
samples.
Methods: We evaluated the methylation profiles of Zp and Rp by methylation-specific PCR (MSP) and bisulfite
genomic sequencing (BGS), as well as BZLF1 and BRLF1 expression by semiquantitative reverse transcription (RT)-
PCR in tumors of epithelial, NK- and B-cell origins.
Results: We found that both Zp and Rp were hypermethylated in all studied EBV-positive cell lines and tumors of
lymphoid (B- or NK cell) or epithelial origin, while unmethylated Zp and Rp alleles were detected in cell lines
expressing BZLF1 and BRLF1. Following azacytidine treatment or combined with trichostatin A (TSA), the expression
of BZLF1 and BRLF1 was restored along with concomitant promoter demethylation, which subsequently induced
the reactivation of early lytic gene BHRF1 and late lytic gene BLLF1.
Conclusions: Hypermethylation of Zp and Rp mediates the frequent silencing of BZLF1 and BRLF1 in EBV-
associated tumors, which could be reactivated by demethylation agent and ultimately initiated the EBV lytic
cascade.
Background
Epstein Barr virus (EBV) is a tumor virus associated with
multiple human malignancies of lymphoid or epithelial
origin, including Burkitt lymphoma (BL), Hodgkin dis-
ease (HD), nasopharyngeal carcinoma (NPC), gastric car-
cinoma (GsCa), nasal NK-lymphoma and posttransplant
lymphoproliferative disease (PTLD), with more than 90%
of adults infected in the world [1,2]. EBV has two types
of infection in cells: latent or lytic. It persists in the
human host as lifelong latent infection, which requires
periodically reactivation of lytic genes and viral replica-
tion for maintaining its latency [3]. Two immediate-early
(IE) proteins, BZLF1 (Zta) and BRLF1 (Rta), are essential
to the switch from latent to lytic infection [4].
Epigenetic regulation of EBV genome is a fundamental
regulatory mechanism determining different types of EBV
infections in its associated tumors [5-8]. Several latent or
lytic genes, including EBV nuclear antigens (EBNA-2, 3A,
3B, 3 C), latent membrane protein 1 (LMP1), IE antigens
(Zta, Rta) and lytic cycle viral kinases, have been identified
tightly controlled by the CpG methylation of various EBV
promoters [1,5,9,10], such as W promoter (Wp), C promo-
ter (Cp), Q promoter (Qp), F promoter (Fp), LMP1
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(Zp) and R promoter (Rp). The precise epigenetic regula-
tion ensures the production of viral progeny without
releasing viral antigens detectable by host immune system.
Meanwhile, reactivation of viral genes from latency by
demethylation agents could serve as a therapeutic strategy
for EBV-associated tumors [1,10-12].
Our previous work characterized the CpG methylation
of EBV major latent promoters Qp, Fp and Cp by genomic
sequencing [13,14]. Recent studies of IE genes have been
focused on the methylation-dependent binding and activa-
tion of Zta to Rp and other viral promoters [15-17], while
the overall methylation status of Zp and Rp in tumor cells
still remains unclear. Here, we studied the methylation
profiles of Zp and Rp in a series of EBV-positive cell lines
and primary tumors of epithelial, NK- or B-cell origin. We
also evaluated the effect of demethylation agent on the
reactivation of BZLF1 and BRLF1 in EBV-positive cell
lines.
Methods
Cell lines and tumor samples
B95-8 is an EBV-immortalized lymphoblastoid cell line.
Rael, Akata, Wanyonyi (Wan), Raji, Namalwa, and AG876
are EBV-positive BL cell lines [13,14]. SNK6 and NK-YS
a r eE B V - p o s i t i v eN K - c e l ll y m p h o m ac e l ll i n e s[ 1 3 , 1 4 ] .
C666-1 is EBV-positive NPC cell line [18]. SNU719 and
YCCEL1 (Rha, Tao, et al, unpublished) are EBV-positive
gastric carcinoma cell lines [19,20]. All cell lines were cul-
tivated at 37°C in RPMI 1640 supplemented with 10%
fetal bovine serum (FBS), 1 mmol/L glutamine, 100 U/ml
penicillin and streptomycin (I n v i t r o g e n ,C A ) .C e l ll i n e s
were maintained at 37°C in cRPMI 1640. 5-aza-dC
(Sigma-Aldrich, St Louis, MO) was used at different con-
centrations and time to treat Rael, NK-YS and C666-1 cell
lines. Other cell lines were treated with 10 μmol/L 5-aza-
dC (Aza, Sigma-Aldrich, St. Louis, MO) for 3 days or
further treated with 100 nmol/L trichostatin A (TSA, Cay-
man Chemical Co., Ann Arbor, MI) for additional ~16 h
as described previously [21,22]. Archival tumor DNA sam-
ples have been previously described [21,23-25]. The study
was approved by Johns Hopkins Medicine Institutional
Review Board.
Semiquantitative reverse transcription (RT)-PCR
Reverse transcription using random hexamer and RT-PCR
using Go-Taq (Promega, Madison, WI) were performed as
previously, with GAPDH as a control [26]. Sequences of
primers are listed in Table 1.
DNA bisulfite treatment and methylation analysis
Bisulfite modification of DNA, methylation-specific PCR
(MSP), and bisulfite genomic sequencing (BGS) were car-
ried out as described [14,26]. Bisulfite-treated DNA was
PCR amplified with strand-specific primers (for bisulfite-
converted top strand of Zp and Rp) for BGS. MSP and
BGS primers of Zp and Rp are listed in Table 1.
Results
Analysis of CpG sites in Z and R promoters
The two IE transcripts derived from EBV genome are
shown in Figure 1A, BZLF1 and BRLF1 are located adja-
cent to each other on the EBV genome. BZLF1 mRNA
(~1.0 kb) can be transcribed from both Zp and Rp, but
its protein product Zta mainly derived from Zp. BRLF1
mRNA (~4.0 kb) is transcribed from Rp and encodes Rta.
We evaluated the distribution of CpG sites and transcrip-
tional regulatory motifs in Zp and Rp. In Zp, only few
CpG sites exist in the “ZI” and “ZII” motifs, which are
the critical elements for activation of Zp by binding of
several transcript factors including CREB, ATF1/2,
MEF2D and Smad3/Smad4. The other negative regula-
tory motifs in Zp, like the proximal ZV element for bind-
ing of zinc-finger E-box binding factor (ZEB), and distal
elements for binding of transcription factors YY1 and
E-box binding protein (E2-2), show scattered distribution
of CpG sites (Figure 1B). In Rp, two Zta-responsive ele-
ments (RpZRE2 and RpZRE3) contain several CpG sites,
mainly responsible for BRLF1 transcription, while other
regulatory elements, such as Sp1, EGR-1, contain only
1-2 CpG sites (Figure 1C). Thus, promoter CpG methyla-
tion of Zp and Rp may regulate BZLF1 and BRLF1 activa-
tion in EBV life cycle.
Methylation status of Zp and Rp in EBV-positive cell lines
of epithelial, NK- or B-cell origins
We then examined the expression of BZLF1 and BRLF1 in
EBV-positive tumor cell lines. Results showed that BZLF1
and BRLF1 were readily expressed in EBV-positive cell
lines (C666-1, YCCEL1, B95-8, and AG876), with expres-
sion of early lytic gene BHRF1 and late lytic gene BLLF1
also detected in these cell lines. In addition, weak expres-
sion of BRLF1 was detected in Raji cells but without
BZLF1 (Figure 2A). SUN719 showed only trace expression
of BZLF1, BRLF1 and lytic BHRF1 but weak expression of
BLLF1.
Next, we used methylation-specific PCR (MSP) to eval-
uate the promoter methylation of Zp and Rp. Primers
were designed to specifically amplify a region containing
the dense CpG sites in Zp and Rp. Zp and Rp methyla-
tion was detected in all EBV-positive cell lines, while
unmethylated alleles were mainly seen in cell lines
expressing BZLF1 and/or BRLF1 ( F i g u r e2 B ) .T of u r t h e r
confirm the MSP results and characterize the methyla-
tion status of Zp and Rp in more detail, we performed
high-resolution bisulfite genome sequencing (BGS) analy-
sis of 18 CpG sites and 20 CpG sites spanning Zp and Rp,
respectively. In EBV-positive BL cell lines Real, Akata,
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both Zp and Rp, while relatively more unmethylated
alleles in Zp and Rp were detected in B95-8 and Wan cell
lines which are with high level of spontaneous EBV lytic
replication [27,28]. Notably, three CpG sites (#12-14) in
Zp were always unmethylated (Figure 2C, D, Table 2).
These results suggest that promoter methylation is clo-
sely related to the transcriptional repression of BZLF1
and BRLF1 in EBV-positive cell lines.
Zp and Rp methylation in EBV-positive tumors
EBV-positive tumors of epithelial or lymphoid origin
including NPC, BL and PTLD samples, as well as two
nude mice-passaged undifferentiated
NPC tumors (C15 and C18) were studied. MSP analysis
showed that Zp and Rp methylation was detected in vir-
tually all 38 NPC tumors, with unmethylated Zp and Rp
only detected in rare cases (Figure 3A, B), well correlated
with the general silencing of BZLF1 and BRLF1 in NPC
(Figure 3C).
We further studied the detailed methylation profiles of
Zp and Rp by BGS in EBV-positive tumors. Results
revealed that both Zp and Rp were heavily methylated in
all studied samples, but relatively more unmethylated
alleles in Zp were observed in PTLD patients (Figure 4A,
B). Again, we observed that the three CpG sites (#12-14)
in Zp were unmethylated in virtually all studied tumors
(Figure 4A). These results are summarized in Table 2.
Restoration of BZLF1 and BRLF1 expression by
demethylation in EBV-positive cell lines
To determine whether methylation directly mediates
the transcriptional repression of BZLF1 and BRLF1,
Rael, NK-YS and C666-1 were treated with 5-aza-2’-
deoxycytidine (5-aza-dC), a DNA methyltransferase
inhibitor. Rael treated with 5-aza-dC at different con-
centrations (0.005, 0.015, 0.03, 0.06, 0.5 and 1 μM) for
72 h. MSP analysis showed that unmethylated Rp and
Zp alleles were increased in a dose-dependent manner,
with significant demethylation of Rp and Zp observed
by treatment with 1 μM 5-aza-dC. Subsequently, 1 μM
of 5-aza-dC was chosen to evaluate the demethylation
of Zp and Rp for different indicated times (5 h, 24 h,
30 h, 48 h) in Rael cell line. It was found that both Zp
and Rp were demethylated in a time-dependent man-
ner (Figure 5A, B). Similarly, NK-YS and C666-1 cells
treated with 5-aza-dC at different concentrations
showed obvious demethylation of Zp and Rp, com-
pared with untreated cells (Figure 5C, D). Concomi-
tantly, Zp and Rp alleles were partially demethylated
after 5-aza-dC treatment by high-resolution BGS analy-
sis (Figure 5E, F, Table 2),
Table 1 Sequences of primers used in this study
vp Primers Sequence (5’-3’) Product size Annealing Temp.(°C) Cycles
RT-PCR BZLF1F GGGAGAAGCACCTCAACCTG 255-bp 55 35
BZLF1R TTGCTTAAACTTGGCCCGGC
BRLF1F CAAACAGACGCAGATGAGGC 443-bp 55 35
BRLF1R GCGGTGCCTATGGTGGCAGG
BHRF1H2 GTCAAGGTTTCGTCTGTGTG 213-bp 55 35
BHRF1H3 TTCTCTTGCTGCTAGCTCCA
BLLF1F GTGGATGTGGAACTGTTTCCAG 230-bp 55 35
BLLF1R CTGTATCCACCGCGGATGTCAC
BARTA3 AGAGACCAGGCTGCTAAACA 232-bp 55 35
BARTA4 AACCAGCTTTCCTTTCCGAG
GAPDHF GATGACCTTGCCCACAGCCT 303-bp 55 23
GAPDHR ATCTCTGCCCCCTCTGCTGA
MSP Zpm1 TCGGATTTTCGTGGGTTAATC 101-bp 64 42
Zpm2 CGAAACTAACGTTAAAAATCCG
Zpu1 ATTTGGATTTTTGTGGGTTAATT 101-bp 62 40
Zpu2 CCAAAACTAACATTAAAAATCCA
Rpm1 TAGGTATTTTGGATATTCGTAC 172-bp 64 42
Rpm3 GATTTAATCCCAACCGCCG
Rpu1 TGTAGGTATTTTGGATATTTGTAT 78-bp 62 40
Rpu2 CAAATCATTACTCCAAACTATCA
BGS ZpMZP1 AAAAAACACCTAATATAAATCAAA 814-bp 62 42
ZpSC22 GTTAAAGAGGATTAGGTTTTTTT
RpMRP1 TCTTTTATAAACCATTAACATAAA 599-bp 60 42
RpMRP2 GAGATTGATAGGATTATATTGT
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or combined with the histone deacetylase inhibitor
(HDACi) trichostatin A (TSA) treatment, the expression
of BZLF1 and BRLF1 was dramatically increased in
EBV-positive epithelial cell lines, as measured by RT-
PCR, along with obviously induced expression of early
lytic gene BHRF1 and late lytic gene BLLF1 (Figure 6A,
B, C), suggesting the initiation of EBV-lytic cascade by
Figure 1 Transcription of EBV immediate-early (IE) genes. (A) The locations of two immediate-early (IE) genes, BZLF 1 and BRLF1, the two IE
promoters, Zp and Rp, are shown. (B, C) Schematic drawing of the structure of Zp and Rp including the distribution of CpG sites, transcriptional
elements and the location of analyzed MSP sites and BGS region. HI: the multiply repeated sequence motif. ZI, ZII and ZIII: three positive
regulatory cis-acting elements. ZI motifs (ZIA, ZIB, ZIC, and ZID): AT-rich sequences. ZRE: Zta-response element. Shadowed region in Zp indicates
a region not methylated in any sample. Shadowed region in Rp indicates the binding site for Zta.
Figure 2 (A, B) The expression of BZLF1, BRLF1, BHRF1 (lytic) and BLLF1 examined by RT-PCR, and methylation of Zp and Rp analyzed by
MSP in EBV-positive cell lines. M, methylated; U, unmethylated. (C, D) BGS analyses of Zp and Rp methylation status in Burkitt lymphoma (BL) and
lymphoid (LCL) cell lines. Circles, CpG sites analyzed; row of circles, an individual promoter allele sequenced; Filled circle, methylated; empty circle,
unmethylated. “x” circle, CpG site abolished by sequence variation or undetermined methylation status due to unconverted C in nearby CpN site.
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Page 4 of 10Table 2 Methylation status of Zp and Rp in EBV-associated cell lines and tumors
EBV-associated cell lines and tumors Zp methylation status
(Methylated CpG sites, %)
Rp methylation status
(methylated CpG sites, %)
Cell lines
Akata 67% 59%
B95-8 17% 36%
C666-1 75% 99%
Namalwa 46% 53%
Raji 60% 87%
Rael 67% 83%
Wan 18% 29%
Nude mice-passaged tumors
C15 68% 96%
C18 56% 59%
Tumors
NPC
NPC1 58% 97%
NPC2 92% 88%
NPC12 70% 87%
BL
BL3 62% 80%
BL5 53% 82%
BL10 67% 82%
PTLD
PTLD2 32% 64%
PTLD4a 44% 85%
PTLD8 22% 70%
PTLD10 47% 73%
PTLD19 53% 80%
PTLD20 75% 80%
Figure 3 (A, B, C) Representative MSP analysis of Zp and Rp methylation. M, methylated; U, unmethylated. NPC, nasopharyngeal carcinoma.
(D) RT-PCR analysis of BZLF1 and BRLF1 expression in primary NPC.
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of Rp methylation after 5-aza-dC treatment with TSA in
YCCEL1 and SNU719. Detailed mapping of Rp by BGS
analysis revealed Rp demethylation after 5-aza-dC treat-
ment combined with TSA as expected, while the critical
sites of Rp (CpG site #13-15) still maintain partially
methylated required for Zta activation (Figure 6D), indi-
cating epigenetic-mediated silencing of BZLF1 and
BRLF1 in EBV-associated epithelial tumors.
Discussion
This study characterized the CpG methylation profiles of
EBV immediate-early lytic promoters Zp and Rp in cell
lines and tumors of epithelial or lymphoid origin, and
further evaluated the reactivation of BZLF1 and BRLF1 by
demethylation treatment. We found that Zp and Rp were
frequently methylated in all EBV-positive cell lines and
tumors, whereas unmethylated Zp and Rp were mainly
present in EBV-positive cell lines with lytic activities, along
with the expression of BZLF1 and BRFL1.W ed i dn o t
observe major difference in Zp and Rp methylation in cell
lines/or tumors of epithelial, NK- or B-cell origin.
We also demonstrated that demethylation of Zp and
Rp by treatment with 5-aza-dC alone or combined with
TSA resulted in the re-expression of BZLF1 and BRLF1
and activation of EBV lytic cycle. It has been identified
that DNA synthesis inhibitors have no effect on DNA
methylation by using four different inhibitors of DNA
replication [29]. Although DNA synthesis inhibitors will
delay some of the cytosine methylation, all delayed DNA
methylation will be finally completed prior to the subse-
quent S phase. Thus, in our study, DNA methylation
inhibitors are mainly responsible for Zp and Rp demethy-
lation and initiation of lytic cascade, while other events
indirectly leading to EBV reactivation also cannot be
ruled out.
In EBV-positive cell lines except for B95-8, Wan and
AG876, only very few % of cells or no cell undergoing
spontaneous lytic infection without much lytic virion
DNA, thus the methylation status of Zp and Rp detected
represents the latent viral genome but not the virion gen-
ome, while in B95-8, Wan and AG876 cell lines with sig-
nificant % of cells undergoing spontaneous lytic infection,
the methylation status detected probably represents both
latent and viral genomes (Figure 2C, D). Similarly, in EBV-
positive tumors with rare cell undergoing spontaneous
lytic infection, methylation status represents the latent
genome [1]. In our study, lower level of methylation was
only observed in B95-8 and Wan cell lines, but not in
other EBV-positive cell lines and primary tumors,
Figure 4 (A, B) Methylation profiling of Zp and Rp of multiple EBV-associated tumors. NPC, nasopharyngeal carcinoma; BL, Burkitt
lymphoma; PTLD, posttransplant lymphoproliferative disease. Circles, CpG sites analyzed; row of circles, an individual promoter allele sequenced;
Filled circle, methylated; empty circle, unmethylated. “x” circle, CpG site abolished by sequence variation or undetermined methylation status due
to unconverted C in nearby CpN site.
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replication only in B95-8 and Wan.
The existence of a small proportion of cells expressing
viral lytic genes is essential for the success maintenance of
EBV latency in host cells with a highly methylated viral
genome [1,3]. As viral transactivator proteins, Zta is
unique to initiate the entire EBV lytic cascade by transacti-
vating a series of lytic gene promoters, but Rta appears to
be more effective in epithelial cells [30,31]. Increased evi-
dences have shown that Zta initiates EBV lytic infection
mainly from a methylated viral genome, whereas Rta initi-
ates lytic infection mainly from an unmethylated genome
[15,16,32,33]. Rp methylation inhibits Rta expression, how-
ever it enhances the ability of Zta to activate Rp [16]. In
line with reported studies, we found that either the Rp-
ZRE2 (CpG site #13-14) or/and the ZRE3 (CpG site #15)
were heavily methylated in virtually all EBV-positive BL,
LCL and NPC cell lines and tumors, but less methylated
in Wan and B95-8 cells with basal lytic activity. A CpG
methylation-free zone (three CpG sites #12-14) in Zp,
located in regulatory elements YY1 and E2-2, is possibly
responsible for the initial activation of BZLF1.T h u s ,Z p
and Rp are regulated by both CpG methylation and cellu-
lar transcription factors, indicating the complexity of the
regulation of BZLF1 and BRLF1 in EBV-associated tumors
[34].
DNA methylation plays a crucial role in allowing EBV
to escape from the detection of host immune system.
Conversely, pharmacologic reversal of viral gene methyla-
tion and activation of gene expression would resensitize
host’s immune surveillance or enhance its response to
immunogenic viral antigens [10]. The efficacy of DNA
methyltransferase inhibitors in hematologic diseases,
including myelodysplastic syndromes (MDS) and acute
myeloid leukemia, has been successfully evaluated by
multiple clinical trials [35-37]. 5-azacytidine has been
now approved as the first-line treatment of high-risk
MDS [38,39]. Our group has firstly reported the achieve-
ment of successful demethylation of EBV viral antigen
promoters including Cp, Wp, LMP1p, Zp and Rp, in
NPC patients with azacitidine treatment [1,10-12]. When
combined with other chemotherapy drugs and histone
Figure 5 (A-D) Pharmacologic demethylation with 5-aza-dC at indicated concentrations and time points analyzed by MSP in Rael, NK-
YS and C666-1 cell lines. Each bottom panel is the plotted densitometry ratios as % of methylation (U/U + M) of Zp and Rp. M, methylated; U,
unmethylated. (E, F). Detailed BGS analysis of demethylation after 5-aza-dC treatment in Rael and C666-1 cell lines. “x” circle, CpG site abolished
by sequence variation or undetermined methylation status due to an unconverted C in nearby CpN site.
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Page 7 of 10deacetylase inhibitors (HDACi), DNMT inhibitors should
have even brighter perspective in the therapeutics of
EBV-associated tumors (Figure 7) [40].
Conclusions
Collectively, our study found that frequent silencing of
BZLF1 and BRLF1 by hypermethylation of Zp and Rp
could be reactivated by demethylation agent, resulting in
the initiation of the EBV lytic cascade in EBV-associated
tumors. Our study helps to understand epigenetics-
related EBV pathogenesis and further develop target
therapy for EBV-associated tumors.
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Figure 6 (A, B, C) Restoration of BZLF1 and BRLF1 expression, as well as BHRF1 (lytic) and BLLF1 by 5-aza-dC treatment or combined
with HDACi-TSA analyzed by RT-PCR. BART as an internal control for EBV latent gene expression. (D) Methylation profiling of Rp by detailed
BGS analysis of demethylation after 5-aza-dC treatment with TSA in YCCEL1 and SNU719 cell lines.
Figure 7 Model of demethylation inducing EBV lytic cascade in
EBV-positive tumor cells.
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